(E)-1,3-Dichloro-2-methyl-1-propene | 35329-41-0

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 乙烯基卤化物
• 英文名称: (E)-1,3-Dichloro-2-methyl-1-propene
• 英文别名: E-1,3-dichloro-2-methyl-1-propene；E-2-methyl-1,3-dichloro-1-propene；(E)-2-methyl-1,3-dichloropropene；(E)-1,3-Dichlor-2-methylpropen；chloro-2-chloromethyl-1-propene；1,3-Dichloro-2-methyl-1-propene；(E)-1,3-dichloro-2-methylprop-1-ene
• CAS: 35329-41-0
• 化学式: C₄H₆Cl₂
• 分子量: 124.998
• InChiKey: ZWZWQSKCVXIXQJ-DUXPYHPUSA-N

物化性质

• 沸点：
  132 °C(Press: 758 Torr)
• 密度：
  1.1667 g/cm3
• 保留指数：
  832.8

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  6
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  (E)-1,3-Dichloro-2-methyl-1-propene 生成 3-methylene-1,6-dithiacyclooctane
  参考文献：
  名称：

  Polymerisable monomers and polymers

  摘要：

  本发明涉及具有以下公式化合物的制备方法：聚合物、共聚物或包含它们或它们作为自由基聚合的单体或共单体的块共聚物，以及在制造粘合剂、牙科复合材料或光学镜头中的用途。

  公开号：

  US06043361A1
• 作为产物：
  描述：

  (E)-3-chloro-2-methylpropen-1-ol 在 三苯基膦 作用下， 以 四氯化碳 为溶剂， 反应 48.0h， 生成 (E)-1,3-Dichloro-2-methyl-1-propene
  参考文献：
  名称：

  Paasivirta, Jaakko; Laihia, Katri; Kleinpeter, Erich, Chemische Berichte, 1983, vol. 116, # 2, p. 522 - 526

  摘要：

  DOI：

文献信息

• Cyclic substituted fused pyrrolocarbazoles and isoindolones
  申请人：Cephalon, Inc.

  公开号：US20040186157A1

  公开（公告）日：2004-09-23

  The present invention is directed to cyclic substituted fused pyrrolocarbazoles and isoindolones. The invention also is directed to methods for making and using the cyclic substituted fused pyrrolocarbazoles and isoindolones.

  本发明涉及环替代融合吡咯咯咯吡咯咯咯和异吲哚酮。该发明还涉及制备和使用环替代融合吡咯咯咯吡咯咯咯和异吲哚酮的方法。
• Perfluorinated amide salts and their uses as ionic conducting materials
  申请人：——

  公开号：US20020009650A1

  公开（公告）日：2002-01-24

  The invention concerns ionic compounds in which the anionic load has been delocalized. A compound disclosed by the invention is comprised of an amide or one of its salts, including an anionic portion combined with at least one cationic portion M +m in sufficient numbers to ensure overall electronic neutrality; the compound is further comprised of M as a hydroxonium, a nitrosonium NO + , an ammonium —NH 4 +, a metallic cation with the valence m, an organic cation with the valence m, or an organometallic cation with the valence m. The anionic portion matches the formula R F —SO x —N − Z, wherein R F is a perfluorinated group, x is 1 or 2, and Z is an electroattractive substituent. The compounds can be used notably for ionic conducting materials, electronic conducting materials, colorants, and the catalysis of various chemical reactions.

  该发明涉及离子化合物，其中阴离子载荷已被解离。该发明揭示的一种化合物由酰胺或其盐之一组成，包括与至少一个阳离子部分M+min结合以确保整体电子中性；该化合物进一步由M作为氢氧离子、亚硝基 NO+、铵离子—NH4+、具有价态m的金属阳离子、具有价态m的有机阳离子，或具有价态m的有机金属阳离子组成。阴离子部分符合公式RF—SOx—N−Z，其中RF是全氟化基团，x为1或2，Z是一个电子吸引取代基。这些化合物可以用于离子导电材料、电子导电材料、着色剂以及各种化学反应的催化。
• [EN] SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES<br/>[FR] INHIBITEURS DE METALLOPROTEASES MATRICES A BASE D'HYDROXAMATES CYCLIQUES SUBSTITUES
  申请人：INCYTE CORP

  公开号：WO2005037826A1

  公开（公告）日：2005-04-28

  The present invention provides compounds of the formula I: its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula I are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.

  本发明提供了公式I的化合物：其对映异构体，二对映异构体，混合物，前药，结晶形式，非晶形式，无定形形式，溶剂化物，代谢物和药学上可接受的盐，其中环A取代基在以下披露中被完全定义。公式I的化合物是金属蛋白酶抑制剂，如基质金属蛋白酶和剪切酶的抑制剂，并且在治疗风湿性关节炎，牛皮癣，肿瘤性疾病，过敏和所有需要MMPs抑制的疾病中有用。
• Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
  申请人：Li Yun-Long

  公开号：US20050113344A1

  公开（公告）日：2005-05-26

  The present invention provides compounds of the formula I: its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula I are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.

  本发明提供了I式化合物：其对映体、非对映异构体、混合物、前药、晶体形态、非晶体形态、无定形形态、溶剂化物、代谢物和药学上可接受的盐，其中环A的取代基在以下披露中被充分定义。I式化合物是金属蛋白酶抑制剂，例如基质金属蛋白酶和脱落素酶，并且在治疗类风湿性关节炎、牛皮癣、肿瘤性疾病、过敏和所有需要抑制MMPs的疾病中有用。
• Aza spiro alkane derivatives as inhibitors of metalloproteases
  申请人：——

  公开号：US20040259896A1

  公开（公告）日：2004-12-23

  The present invention provides a compound of Formula I or Formula II: 1 enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.

  本发明提供了公式I或公式II的化合物：1对映异构体，对映体，前药，溶剂化物，代谢物或其药学上可接受的盐，其中组分变量在此处提供。公式I和II的化合物是金属蛋白酶调节剂，可用于治疗与金属蛋白酶活性相关的疾病，如关节炎，癌症，心血管疾病，皮肤疾病，炎症和过敏症。